PrimeRFP SCOUT · Federal Contract Recompete Brief

75F40122C00154DESIGN a two-stage process for USING — Brigham & Womens Hospital Inc

Brigham & Womens Hospital Inc holds $20.7M across 79 federal awards, concentrated at Department of Veterans Affairs (VA). This PIID sits alongside 5 related awards in the incumbent pipeline. Competition previously drew 165 offers. Set-aside status: Unrestricted. Recompete timing centers on the Jun 27, 2027 PoP end — agencies typically plan 12–18 months ahead.

Fda Office Of Acq Grant Svcs
Awarding office
Brigham & Womens Hospital Inc
Recipient
Jun 27, 2027
PoP end
$2.7M
Obligated
$2.7M
Potential
541714
NAICS
AN11
PSC
Unrestricted
Set-aside
165 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Contract facts

Unrestricted
Contract number75F40122C00154
AgencyFda Office Of Acq Grant Svcs
Awarding officeFda Office Of Acq Grant Svcs
Awarding agencyDepartment of Health and Human Services (HHS)
Funding agencyDepartment of Health and Human Services (HHS)
IncumbentBrigham & Womens Hospital Inc
CAGE0W3J1
UEIQN6MS4VN7BD1
NAICS541714

No full NAICS 541714 intel page yet. Browse NAICS intelligence

PSCAN11
Place of performanceSILVER SPRING MD
Pricing typeFirm Fixed Price
Extent competedFull And Open Competition
PoP startSep 27, 2022
PoP end (current)Jun 27, 2027
Obligated$2.7M
Current value$2.7M
Potential value$2.7M

DESIGN A TWO-STAGE PROCESS FOR USING RWE TO SUPPORT LABELING EXPANSIONS FOR EFFECTIVENESS CLAIMS THAT IS ALIGNED WITH REGULATORY REQUIREMENTS/DEMONSTRATE AND EMPIRICALLY TEST THE PROCESS WITH HISTORICAL AND ONGOING RCTS FOR SUPPLEMENTAL INDICATIONS/ is a federal Unrestricted award for Fda Office Of Acq Grant Svcs held by Brigham & Womens Hospital Inc. Estimated value $2.7M ($2.7M obligated). Current period of performance ends Jun 27, 2027. Last award drew 165 bidders. Place of performance: SILVER SPRING MD.

DESIGN A TWO-STAGE PROCESS FOR USING RWE TO SUPPORT LABELING EXPANSIONS FOR EFFECTIVENESS CLAIMS THAT IS ALIGNED WITH REGULATORY REQUIREMENTS/DEMONSTRATE AND EMPIRICALLY TEST THE PROCESS WITH HISTORICAL AND ONGOING RCTS FOR SUPPLEMENTAL INDICATIONS/

Recompete timing

Public
● Expiring in 273 days

Current PoP ends Jun 27, 2027 (273 days remaining). Agencies typically plan 12–18 months ahead — at 9.0 months out, that window is already open. The buying decision is likely already in motion.

Bonuses end Sept 30

Want the durability read on 75F40122C00154? One Pursuit Analysis, $500, inside 48 business hours.

  • 48 business hours
  • $500
  • Credits toward the Pack
Buy one Pursuit Analysis — $500

Incumbent footprint

Public record

Brigham & Womens Hospital Inc — $20.7M obligated across 79 awards (firm-wide, all agencies) · lead buyer Department of Veterans Affairs (VA).

% of firm-wide obligated ($20.7M) · all agencies
Department of Veterans Affairs (VA)$13.0M · 63%Department of Health and Human Services (HHS)$6.9M · 33%National Aeronautics and Space Administration (NASA)$1.5M · 7%Department of Justice (DOJ)$14K · 0%
Open full company profile →

Related awards

Same incumbent
80ARC022CA007
MODELING ANTHRACYCLINE-TRIGGERED VASCULAR DYSFUNCTION
$2.0M
Sep 26, 2026
75N95021P00564
NANOSIMS ANALYSIS OF MITOCHONDRIAL METABOLISM IN MOUSE MODELS OF NEURODEGENERATION. ESTIMA…
$195K
Sep 26, 2026
36C24E25N0234
BIOINFORMATICS RESEARCH SUPPORT
$559K
Sep 13, 2026
36C24E25N0231
BIOINFORMATICS RESEARCH SUPPORT - DIV OF AGING
$542K
Sep 13, 2026
36C24E25N0235
BIOINFORMATICS RESEARCH SUPPORT
$399K
Sep 13, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

More in SCOUT
Size up the competition →Research the incumbent →

Frequently asked questions

What is contract 75F40122C00154?

75F40122C00154 (DESIGN a two-stage process for USING) is a Fda Office Of Acq Grant Svcs award with a potential value of $2.7M, currently held by Brigham & Womens Hospital Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75F40122C00154?

Fda Office Of Acq Grant Svcs awarded 75F40122C00154 to Brigham & Womens Hospital Inc (potential $2.7M).

Who is the incumbent on 75F40122C00154?

Brigham & Womens Hospital Inc is the incumbent with $20.7M across 79 related awards in SCOUT’s public footprint. The current period of performance ends Jun 27, 2027.

When does Brigham & Womens Hospital Inc’s 75F40122C00154 come up for recompete?

SCOUT tracks a period-of-performance end of Jun 27, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Want the durability read on 75F40122C00154? One Pursuit Analysis, $500, inside 48 business hours.

One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.

Get the free Exposure Check

No card · under a minute · then the Sprint menu

Buy one Pursuit Analysis — $500

Credits toward the Sprint Pack

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/75F40122C00154